Business Context and Reporting Period
This Form 8-K filing by Anavex Life Sciences Corp. (Nevada corporation) reports corporate governance changes effective May 7, 2014. The report was filed on May 13, 2014, by CEO Christopher Missling, PhD.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation arrangements related to board appointments.
Material Changes
The Board of Directors appointed two new members effective May 7, 2014:
- Bernd Metzner: Appointed as a Board member and Chairman of the Audit Committee.
- Elliot Favus: Appointed as a Board member.
Both appointments are to serve until successors are elected or until earlier resignation/removal.
Compensation and Management Commentary
The Company granted stock options and cash compensation to the new directors:
- Stock Options: Both Mr. Metzner and Mr. Favus received options to purchase 150,000 shares of common stock each. These options vest annually over a three-year period, commencing on the first anniversary of the Effective Date.
- Cash Compensation: Mr. Metzner will receive $2,500 per quarter, commencing in the third quarter of fiscal year 2014. No cash compensation is mentioned for Mr. Favus in this text.
A press release announcing these appointments was issued on May 8, 2014, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 150,000 options granted to each director.
- Confirm the total number of authorized shares and the potential dilution impact of these grants.
- Review the attached press release (Exhibit 99.1) for additional context on the directors' qualifications.
- Check subsequent filings for the actual cash payments made to Mr. Metzner starting in Q3 FY2014.